WallStreetZenWallStreetZen

NASDAQ: PMN
Promis Neurosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PMN

Based on 2 analysts offering 12 month price targets for Promis Neurosciences Inc

Min Forecast
$18.00+63.49%
Avg Forecast
$26.50+140.69%
Max Forecast
$35.00+217.89%

Should I buy or sell PMN stock?

Based on 2 analysts offering ratings for Promis Neurosciences Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PMN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates PMN as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their PMN stock forecasts and price targets.

PMN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-06
lockedlocked$00.00+00.00%2025-12-01

1 of 1

Forecast return on equity

Is PMN forecast to generate an efficient return?

Forecast return on assets

Is PMN forecast to generate an efficient return on assets?

Company
-507%
Industry
3.45%
PMN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PMN earnings per share forecast

What is PMN's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$8.37
Avg 2 year Forecast
-$4.57
Avg 3 year Forecast
-$5.19

PMN revenue forecast

What is PMN's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

PMN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PMN$11.01$26.50+140.69%Strong Buy
CUE$30.42N/AN/A
BMEA$1.37$9.50+593.43%Strong Buy
COYA$4.17$15.75+277.70%Strong Buy
CBUS$1.45$9.00+520.69%Buy
View Top Biotech Stocks

Promis Neurosciences Stock Forecast FAQ

Is Promis Neurosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: PMN) stock is to Strong Buy PMN stock.

Out of 2 analysts, 1 (50%) are recommending PMN as a Strong Buy, 1 (50%) are recommending PMN as a Buy, 0 (0%) are recommending PMN as a Hold, 0 (0%) are recommending PMN as a Sell, and 0 (0%) are recommending PMN as a Strong Sell.

If you're new to stock investing, here's how to buy Promis Neurosciences stock.

What is PMN's earnings growth forecast for 2026-2028?

(NASDAQ: PMN) Promis Neurosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.98%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.61%.

Promis Neurosciences's earnings in 2026 is -$39,719,147.On average, 5 Wall Street analysts forecast PMN's earnings for 2026 to be -$75,040,758, with the lowest PMN earnings forecast at -$158,190,105, and the highest PMN earnings forecast at -$41,242,420. On average, 4 Wall Street analysts forecast PMN's earnings for 2027 to be -$40,939,312, with the lowest PMN earnings forecast at -$44,117,462, and the highest PMN earnings forecast at -$37,852,632.

In 2028, PMN is forecast to generate -$46,554,881 in earnings, with the lowest earnings forecast at -$49,214,699 and the highest earnings forecast at -$44,067,243.

What is PMN's revenue growth forecast for 2026-2028?

(NASDAQ: PMN) Promis Neurosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.15%.

Promis Neurosciences's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast PMN's revenue for 2026 to be $0, with the lowest PMN revenue forecast at $0, and the highest PMN revenue forecast at $0. On average, 3 Wall Street analysts forecast PMN's revenue for 2027 to be $0, with the lowest PMN revenue forecast at $0, and the highest PMN revenue forecast at $0.

In 2028, PMN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is PMN's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: PMN) forecast ROA is -507%, which is lower than the forecast US Biotechnology industry average of 3.45%.

What is PMN's Price Target?

According to 2 Wall Street analysts that have issued a 1 year PMN price target, the average PMN price target is $26.50, with the highest PMN stock price forecast at $35.00 and the lowest PMN stock price forecast at $18.00.

On average, Wall Street analysts predict that Promis Neurosciences's share price could reach $26.50 by Feb 6, 2027. The average Promis Neurosciences stock price prediction forecasts a potential upside of 140.69% from the current PMN share price of $11.01.

What is PMN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PMN) Promis Neurosciences's current Earnings Per Share (EPS) is -$22.61. On average, analysts forecast that PMN's EPS will be -$8.37 for 2026, with the lowest EPS forecast at -$17.64, and the highest EPS forecast at -$4.60. On average, analysts forecast that PMN's EPS will be -$4.57 for 2027, with the lowest EPS forecast at -$4.92, and the highest EPS forecast at -$4.22. In 2028, PMN's EPS is forecast to hit -$5.19 (min: -$5.49, max: -$4.91).

What is PMN's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: PMN) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.